Membrane Protein Solution for CAR-T Cell Therapy Development

Online Inquiry

Chimeric antigen receptor (CAR)-T cell therapy aims to redirect a patient's or donor's T cells to specifically target and destroy tumor cells, and has emerged as an efficient approach for immunotherapy of refractory malignancies. Through genetic modification of CARs, T cells are able to recognize tumor-associated surface antigens and are independent of peptide presentation on the major histocompatibility complex (MHC). Since CAR-T cell therapy is a form of immune cellular therapy with clinical efficacy and a specific target, the high target-cell-specificity of CAR-T cells may improve the safety of this cell therapy, thereby expanding the application of this immunotherapy.

CAR-T Cell Therapy Discovery and Development

Overview of CAR-T Cell Therapy

CAR-T immunotherapy has been a great success due to its powerful and long-lasting anti-tumor function. This therapy is achieved by using genetically engineering T-lymphocytes to harness their anti-tumor activity. The recognition and clearance of tumor cells by CAR-T cells rely on CAR molecules and not on the binding of conventional T cell receptors (TCR) and human leukocyte antigens (HLA), thus overcoming the immune escape caused by low human leukocyte antigen (HLA) expression in tumor cells. There are three major step in this therapy, including T cell isolation, T cell modification with CAR, and injection of the modified cells into the patient. CAR-T cells can differentiate into memory T cells, through which long-term anti-tumor activity can be established.

CAR-T cell therapy discovery and development at Creative Proteomics

Candidate screening for CAR-T cell therapies

Our high-quality pure, stable and functional native membrane proteins are compatible with immunizations, phage displays, and synthetic displays and can help customers greatly improve their antibody discovery. In addition, our services can contribute to the discovery of new mechanisms of action and promote a more reliable and in-depth understanding of antibody/antigen recognition.

Evaluate the specificity of CAR-T cell therapies

Rigorous specificity testing is critical for antibody-based drug development, including CAR-T cell therapies. Cross-reactivity assessment of CAR-T cell therapies is essential since even minimal off-target binding can lead to serious adverse effects. Since CAR-T therapies engage the target cells primarily through binding to membrane proteins, we offer membrane protein microarray services to assess the specificity of CAR-T cell binding. We are dedicated to providing the best solutions for profiling specificity of CAR-T cells and other antibody-based therapeutics. With a well-established membrane protein microarray platform containing a variety of membrane proteins, we can help our customers perform comprehensive cross-reactivity assessments.

Off-target identification of CAR-T cell therapies

In addition, membrane protein microarray can be used not only to validate the specificity of antibodies to known membrane protein targets but also to provide additional information by identifying binding to other membrane proteins, thus facilitating the final lead selection in the project to avoid off-target binding.

Explore more about our services

As a leading provider of services in the field of biotechnology, Creative Proteomics offers a wide range of membrane protein-related services including expression, extraction, purification, and screening to meet the needs of different applications, with a focus on drug discovery and development applications. Contact us to learn more about how we can help accelerate your CAR-T cell research. Your project will be thoroughly consulted and discussed so that our platform and services provide the best solution for your project.

Reference

Wei, Jianshu, et al. "Target selection for CAR-T therapy." Journal of hematology & oncology 12 (2019): 1-9.

* For Research Use Only. Not for use in diagnostic procedures.